Article
Oncology
Karan S. Dixit, Sean Sachdev, Christina Amidei, Priya Kumthekar, Tim J. Kruser, Vinai Gondi, Sean Grimm, Rimas Lukas, Martin Kelly Nicholas, Steven J. Chmura, Angela J. Fought, Minesh Mehta, Jeffrey J. Raizer
Summary: This study demonstrates that re-irradiation with bevacizumab and temozolomide is a safe and effective salvage treatment for patients with bevacizumab-refractory high-grade glioma. Patients further from their initial radiotherapy may derive greater benefit from this regimen.
JOURNAL OF NEURO-ONCOLOGY
(2021)
Review
Biochemistry & Molecular Biology
Jacob P. Fisher, David C. Adamson
Summary: The standard of care for high-grade gliomas includes surgical resection, radiation therapy, and temozolomide, which have improved patient survival rates. Besides temozolomide, there are several other FDA-approved treatments for HGG, with tumor treatment fields being the only one shown to significantly improve survival rates.
Review
Oncology
Li Yanchu, Pu Rong, Cao Rong, Zhang Li, Yang Xiaoyan, Wang Feng
Summary: High-grade gliomas are aggressive brain tumors that are difficult to treat. Ozone therapy has shown promising results in preclinical studies and clinical trials for various cancers, but there have been limited studies on gliomas. Optimizing the dosage and timing of ozone therapy remains a challenge. This study provides an overview of ozone therapy in high-grade gliomas, including its mechanisms of action and clinical evidence.
FRONTIERS IN ONCOLOGY
(2023)
Article
Pharmacology & Pharmacy
Riccardo Serra, Antonella Mangraviti, Noah L. Gorelick, Tovi Shapira-Furman, Safwan Alomari, Arba Cecia, Namrata Darjee, Henry Brem, Yakir Rottenberg, Abraham J. Domb, Betty Tyler
Summary: This study tested a novel polymeric matrix that gradually releases ACF at the tumor bed while combining it with TMZ and XRT. The combination therapy of ACF, TMZ, and XRT reduced cell viability and induced apoptosis in glioma cells. The release of ACF was measured in vitro and in vivo, and the efficacy was established in an in vivo gliosarcoma model, showing improved median survival and long-term survival.
EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS
(2022)
Review
Oncology
Katherine Belanger, Timothy H. Ung, Denise Damek, Kevin O. Lillehei, D. Ryan Ormond
Summary: In this retrospective analysis, the efficacy of TMZ chemoradiation for the treatment of high-grade and recurrent meningiomas was compared to historical controls. The results showed no significant difference in PFS and OS between the two groups, suggesting that further research is needed to find novel treatment methods for malignant and recurrent meningiomas.
Article
Oncology
William Kelly, Adolfo Enrique Diaz Duque, Joel Michalek, Brandon Konkel, Laura Caflisch, Yidong Chen, Sarath Chand Pathuri, Vinu Madhusudanannair-Kunnuparampil, John Floyd II, Andrew Brenner
Summary: In this study, TVB-2640 was found to be a well-tolerated oral drug that could be safely combined with bevacizumab in relapsed high-grade astrocytoma patients, showing potential therapeutic effects.
CLINICAL CANCER RESEARCH
(2023)
Review
Neurosciences
Alice Giotta Lucifero, Sabino Luzzi
Summary: High-grade gliomas (HGGs) exhibit resilience against conventional chemotherapies due to their heterogeneous genetic landscape, adaptive phenotypic changes, and immune escape mechanisms. Innovative immunotherapies have been developed to counteract the immunosuppressive capability of gliomas, with active immunotherapies including systemic temozolomide, monoclonal antibodies, and vaccines, and adoptive immunotherapies showing potential treatment options for relapsing gliomas. Further research is needed to assess the efficacy of these immuno-based approaches in treating high-grade gliomas.
Article
Oncology
Yao Yu, Javier Villanueva-Meyer, Matthew R. Grimmer, Stephanie Hilz, David A. Solomon, Serah Choi, Michael Wahl, Tali Mazor, Chibo Hong, Anny Shai, Joanna J. Phillips, Bruce H. Wainer, Michael McDermott, Daphne Haas-Kogan, Jennie W. Taylor, Nicholas Butowski, Jennifer L. Clarke, Mitchel S. Berger, Annette M. Molinaro, Susan M. Chang, Joseph F. Costello, Nancy Ann Oberheim Bush
Summary: The study found that hypermutation induced by temozolomide greatly increased the risk of high-grade disease recurrence in low-grade IDH-mutant glioma patients previously treated with TMZ, and was associated with shorter survival after transformation. Tumors with hypermutation were more likely to develop discontiguous foci of disease in the brain and spine.
Review
Oncology
Maximilian J. Mair, Marjolein Geurts, Martin J. van den Bent, Anna S. Berghoff
Summary: WHO grade II-III gliomas are rare primary brain tumors with longer median survival compared to grade IV glioblastoma. Treatment involves maximal safe resection and adjuvant therapies, with challenges in conducting clinical trials due to rarity and long follow-up times. The 2016 WHO Classification introduced a molecular diagnostic framework for more homogenous subgroups. Available evidence for adjuvant treatment was generated pre-molecular era, emphasizing the need for further research in this field.
CANCER TREATMENT REVIEWS
(2021)
Article
Oncology
Henry S. Friedman, Michael D. Prados, Patrick Y. Wen, Tom Mikkelsen, David Schiff, Lauren E. Abrey, W. K. Alfred Yung, Nina Paleologos, Martin K. Nicholas, Randy Jensen, James Vredenburgh, Jane Huang, Maoxia Zheng, Timothy Cloughesy
Summary: This study evaluated the efficacy of bevacizumab, alone or in combination with irinotecan, in recurrent glioblastoma patients. The results showed that bevacizumab, either alone or in combination, was well tolerated and active in treating recurrent glioblastoma.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Radiology, Nuclear Medicine & Medical Imaging
Beatrice Detti, Silvia Scoccianti, Maria Ausilia Teriaca, Virginia Maragna, Victoria Lorenzetti, Sara Lucidi, Chiara Bellini, Daniela Greto, Isacco Desideri, Lorenzo Livi
Summary: Overall, the analysis confirms the efficacy of bevacizumab in patients with recurrent high-grade gliomas, with an acceptable toxicity profile. The study found that performance status, age at diagnosis, and the use of corticosteroids during bevacizumab therapy were strongly associated with progression-free survival. Long-term responders accounted for more than half of the cohort.
Article
Oncology
Ying Shi, Mengwan Wu, Yuyang Liu, Lanlin Hu, Hong Wu, Lei Xie, Zhiwei Liu, Anhua Wu, Ling Chen, Chuan Xu
Summary: This study aimed to explore the genetic features responsible for TMZ and Bevacizumab resistance in glioma patients. Through analyzing clinical data and conducting cell experiments, it was found that changes in cell morphology and polarity were closely associated with drug resistance, and the expression level of ITGA5 played a crucial role in determining resistance and treatment outcomes.
FRONTIERS IN ONCOLOGY
(2021)
Article
Veterinary Sciences
Benjamin Cartiaux, Alexandra Deviers, Caroline Delmas, Jerome Abadie, Marti Pumarola Battle, Elizabeth Cohen-Jonathan Moyal, Giovanni Mogicato
Summary: Glioma is the most common primary brain tumor in dogs, and studying canine glioma cell lines can provide valuable insights into radiotherapy for human glioma. Dogs develop spontaneous glioma with similarities to humans, and the use of imaging techniques and radiation therapy can be directly transposed from human medicine to dogs. This study aims to fully characterize and evaluate the radiosensitivity of 5 canine glioma cell lines.
FRONTIERS IN VETERINARY SCIENCE
(2023)
Review
Biochemistry & Molecular Biology
Hannah Chatwin, Joselyn Cruz Cruz, Adam L. Green
Summary: Pediatric high-grade gliomas (pHGG) are a lethal and heterogenous category requiring more effective treatment options. The review discusses the history of treatment approaches to pHGG, different molecular subgroups of pHGG, targeted treatment options, and novel approaches such as localized convection-enhanced chemotherapy delivery and immunotherapy. It demonstrates the potential for molecularly driven therapy combined with other novel methods to improve prognosis in pHGG.
Article
Cell Biology
Baiwei Zhang, Cheng Xu, Junfeng Liu, Jinsheng Yang, Qinglei Gao, Fei Ye
Summary: The study revealed that NID1 is overexpressed in glioma tissues, and high NID1 expression is associated with overall survival and temozolomide sensitivity in low-grade glioma patients. NID1 could serve as a potential prognostic biomarker and therapeutic target in this patient population.
Review
Oncology
Evan Rosenbaum, Douglas Marks, Shahzad Raza
HEMATOLOGICAL ONCOLOGY
(2018)
Article
Hematology
Maria-Victoria Mateos, Hilary Blacklock, Fredrik Schjesvold, Albert Oriol, David Simpson, Anupkumar George, Hartmut Goldschmidt, Alessandra Larocca, Asher Chanan-Khan, Daniel Sherbenou, Irit Avivi, Noam Benyamini, Shinsuke Iida, Morio Matsumoto, Kenshi Suzuki, Vincent Ribrag, Saad Z. Usmani, Sundar Jagannath, Enrique M. Ocio, Paula Rodriguez-Otero, Jesus San Miguel, Uma Kher, Mohammed Farooqui, Jason Liao, Patricia Marinello, Sagar Lonial
LANCET HAEMATOLOGY
(2019)
Article
Cardiac & Cardiovascular Systems
Brett W. Sperry, Ibrahim M. Saeed, Shahzad Raza, Kevin F. Kennedy, Mazen Hanna, John A. Spertus
AMERICAN JOURNAL OF CARDIOLOGY
(2019)
Letter
Oncology
Siyang Leng, Divaya Bhutani, Shahzad Raza, Amer Assal, Samuel Pan, Jianhua Hu, Alexander Wei, Markus Mapara, Suzanne Lentzsch
BLOOD CANCER JOURNAL
(2020)
Article
Genetics & Heredity
Ashiq Masood, Trevor Christ, Samia Asif, Priya Rajakumar, Beth A. Gustafson, Leyla O. Shune, Ameen Salahudeen, Drew Nedvad, Suparna Nanua, Agne Paner, Timothy M. Kuzel, Mia Levy, Janakiraman Subramanian, Shahzad Raza
Summary: Non-secretory multiple myeloma (NSMM) is a distinct type of multiple myeloma characterized by the absence of detectable monoclonal protein. A case study reported here showed a relapsed and refractory NSMM patient with TFG-ALK fusion and brain metastasis had a dramatic and durable response to commercially available ALK inhibitors, highlighting the beneficial role of molecular profiling in this target-poor disease.
NPJ GENOMIC MEDICINE
(2021)
Editorial Material
Health Care Sciences & Services
Muhammad Hamza Habib, Sean Marks, Shahzad Raza, Jyoti Malhotra, Mellar P. Davis
JOURNAL OF PALLIATIVE MEDICINE
(2022)
Review
Oncology
Himil Mahadevia, Ben Ponvilawan, Parth Sharma, Ammar Al-Obaidi, Hana Qasim, Jagadish Koyi, Faiz Anwer, Shahzad Raza
Summary: AL amyloidosis is a plasma cell neoplasm characterized by abnormal production of monoclonal immunoglobulin light chains and their deposition in tissues, leading to organ damage. Current treatment approaches, such as autologous stem cell transplantation, are effective but alternative strategies are needed. Medications used for multiple myeloma, such as daratumumab, proteasome inhibitors, and corticosteroids, have become standard of care for AL amyloidosis. Disassembling amyloid deposits holds promise for reversing disease damage, as shown by CAEL-101 and birtamimab. Novel treatment options, including antibody-drug conjugates, bispecific T-cell engagers, and chimeric antigen receptor T cell therapy, are being explored.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
(2023)
Review
Oncology
Danai Dima, Fauzia Ullah, Sandra Mazzoni, Louis Williams, Beth Faiman, Austin Kurkowski, Chakra Chaulagain, Shahzad Raza, Christy Samaras, Jason Valent, Jack Khouri, Faiz Anwer
Summary: Multiple myeloma is a common blood malignancy with limited cure. Recent advances in advanced therapies have improved survival and quality of life, but relapse and drug resistance remain major challenges. This review focuses on the treatment of relapsed/refractory multiple myeloma, highlighting novel modalities like CAR-T cell therapy and bispecific antibodies. Factors like relapse characteristics and patient-related parameters are discussed in relation to drug combination and cellular therapy selection, with the aim of guiding therapeutic decision-making.
Review
Medicine, Research & Experimental
Abbas Bader, Madeline Begemann, Ammar Al-Obaidi, Muhammad Hamza Habib, Faiz Anwer, Shahzad Raza
Summary: Ocular complications of antineoplastic agents can have a significant impact on the quality of life of cancer patients. The introduction of new oncologic treatments has led to an increase in ocular complications, which present unique challenges in patient management. This review highlights the importance of communication between oncologists and ophthalmologists for early detection and management of ocular complications in cancer patients.
Review
Medicine, General & Internal
Razwana Khanam, Beth Faiman, Saba Batool, Mohammed Musa Najmuddin, Rana Usman, Kiran Kuriakose, Arooj Ahmed, Mohammad Ebad Ur Rehman, Zinath Roksana, Zain Syed, Faiz Anwer, Shahzad Raza
Summary: Anti-B-cell maturation antigen therapies have shown promising results in relapsed refractory multiple myeloma, but severe side effects pose a risk to patients. This review focuses on the most common complications post-BCMA therapy, discussing risk factors, pathogenesis, clinical features, and prevention and treatment strategies. FDA-approved agents for adult RRMM patients were analyzed to outline stepwise management of complications.
JOURNAL OF CLINICAL MEDICINE
(2023)
Review
Oncology
Mariam Markouli, Fauzia Ullah, Serhan Unlu, Najiullah Omar, Nerea Lopetegui-Lia, Marissa Duco, Faiz Anwer, Shahzad Raza, Danai Dima
Summary: Multiple myeloma is a common hematologic malignancy with a low survival rate despite advancements in therapy. The introduction of anti-BCMA immunotherapies has changed the treatment paradigm but frequent and significant adverse effects require close monitoring and prompt interventions. This review discusses the toxicities of CAR-T cell and bispecific antibody therapies and provides recommendations for prevention and management.
Article
Medicine, General & Internal
Brett W. Sperry, Ahmed A. Harhash, Furha Cossor, Shahzad Raza
Summary: Immunoglobulin light chain (AL) amyloidosis can cause amyloid fibril deposition in the peripheral and autonomic nerves, leading to resting and orthostatic hypotension. Pulseless electrical activity (PEA) is the most commonly proposed cardiac rhythm associated with sudden death in severe AL cardiac amyloidosis patients. This study describes four patients with severe AL cardiac amyloidosis who experienced witnessed cardiac arrest with pulseless electrical activity due to vasovagal syncope.
CUREUS JOURNAL OF MEDICAL SCIENCE
(2023)
Article
Medicine, General & Internal
Marwa Elsayed, Stephanie Harry, Suprana Nanua, Shayaan Zaidi, Muhammad H. Habib, Shahzad Raza
Summary: Atypical chronic myeloid leukemia (aCML) is a rare disease that is often under-diagnosed. Recent advancements in next-generation sequencing have improved diagnostic accuracy and opened up more targeted treatment options, leading to better outcomes.
CUREUS JOURNAL OF MEDICAL SCIENCE
(2022)
Review
Hematology
Marwa Elsayed, Sara Usher, Muhammad Hamza Habib, Nausheen Ahmed, Jawad Ali, Madeline Begemann, Syed Ahmed Shabbir, Leila Shune, Jaffar Al-Hilli, Furha Cossor, Brett W. Sperry, Shahzad Raza
Summary: AL amyloidosis is a rare and fatal disease caused by the aggregation of misfolded proteins in the extracellular matrix. Treatment strategies for this disease have historically been based on therapies used for multiple myeloma, but success rates vary. Ongoing research is focused on improving treatment outcomes for AL amyloidosis through updates to clinical guidelines and therapeutic approaches.
JOURNAL OF HEMATOLOGY
(2021)
Article
Oncology
Samia Asif, Madeline Begemann, Joseph Bennett, Rawish Fatima, Ash Q. Masood, Shahzad Raza
MOLECULAR AND CLINICAL ONCOLOGY
(2019)